Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: Implications for substance abuse in schizophrenia

Schizophrenia Bulletin

Volumn 39, Issue 3, 2013, Pages 692-702

  Bédard, Anne Marie ^a   Maheux, Jérôme ^a   Lévesque, Daniel ^a   Samaha, Anne Noël ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

antipsychotic drug; conditioned reward; dopamine supersensitivity; immediate early gene; incentive motivation; Pavlovian conditioning

Indexed keywords

HALOPERIDOL; MESSENGER RNA; OLANZAPINE; PROTEIN C FOS; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATION; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; DRUG SEEKING BEHAVIOR; DRUG WITHDRAWAL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; REWARD; SCHIZOPHRENIA; SUBSTANCE ABUSE;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CONDITIONING, CLASSICAL; CUES; DIAGNOSIS, DUAL (PSYCHIATRY); DOPAMINE; DOPAMINE AGENTS; DRUG-SEEKING BEHAVIOR; HALOPERIDOL; MALE; MOTIVATION; NEOSTRIATUM; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 84876535527     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs077     Document Type: Article

References (59)

1. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J Am Med Assoc. 1990;264:2511-2518.
2. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858. (Pubitemid 26264738)
3. Kerfoot KE, Rosenheck RA, Petrakis IL et al. Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophr Res. 2011;132:177-182.
4. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis. 1987;175:641-652. (Pubitemid 17163491)
5. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83. (Pubitemid 32728207)
6. Bedard AM, Maheux J, Levesque D, Samaha AN. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology. 2011;36:1248-1259.
7. Kosten TA, DeCaprio JL, Nestler EJ. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology. 1996;128:304-312. (Pubitemid 26403126)
8. LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology. 1995;121:407-427.
9. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996;40:1155-1163. (Pubitemid 26400880)
10. Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:867-872. (Pubitemid 46661967)
11. Stinus L, Nadaud D, Deminiere JM, Jauregui J, Hand TT, Le Moal M. Chronic flupentixol treatment potentiates the reinforcing properties of systemic heroin administration. Biol Psychiatry. 1989;26:363-371. (Pubitemid 19198222)
12. Roberts DC, Vickers G. The effect of haloperidol on cocaine self-administration is augmented with repeated administrations. Psychopharmacology. 1987;93:526-528. (Pubitemid 18049596)
13. Seeger TF, Gardner EL. Enhancement of self-stimulation behavior in rats and monkeys after chronic neuroleptic treatment: evidence for mesolimbic supersensitivity. Brain Res.1979;175:49-57. (Pubitemid 9257762)
14. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987;91:415-433. (Pubitemid 17038204)
15. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986. (Pubitemid 46438984)
16. Smith RC, Davis JM. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Psychopharmacol Commun. 1975;1:285-293.
17. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic efficacy is greater with transient rather than continuous drug delivery. Biol Psychiatry. 2008;64:145-152.
18. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology. 2009;34:662-671.
19. Arroyo M, Markou A, Robbins TW, Everitt BJ. Acquisition, maintenance and reinstatement of intravenous cocaine selfadministration under a second-order schedule of reinforcement in rats: Effects of conditioned cues and continuous access to cocaine. Psychopharmacology. 1999;140:331-344. (Pubitemid 28562453)
20. Panlilio LV, Weiss SJ, Schindler CW. Cocaine self-administration increased by compounding discriminative stimuli. Psychopharmacology. 1996;125:202-208. (Pubitemid 26184807)
21. de Wit H, Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology. 1981;75:134-143. (Pubitemid 12228819)
22. Ehrman RN, Robbins SJ, Childress AR, O'Brien CP. Conditioned responses to cocaine-related stimuli in cocaine abuse patients. Psychopharmacology. 1992;107:523-529.
23. Creese I, Snyder SH. Chronic neuroleptic treatment and dopamine receptor regulation. Adv Biochem Psychopharmacol. 1980;24:89-94.
24. Severson JA, Robinson HE, Simpson GM. Neurolepticinduced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug. Psychopharmacology (Berl). 1984;84:115-119. (Pubitemid 14032222)
25. van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol. 2008;585:130-136.
26. McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology. 2010;35:1826-1835.
27. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Therap. 2003;305:625-631. (Pubitemid 36459179)
28. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
29. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520. (Pubitemid 30191189)
30. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 2001;25:633-641. (Pubitemid 32995945)
31. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry. 2002;7:317-321. (Pubitemid 34280640)
32. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd ed. New York: Academic Press; 1986.
33. Vanderschuren LJ, Schoffelmeer AN, Van Leeuwen SD, Hof L, Jonker AJ, Voorn P. Compartment-specific changes in striatal neuronal activity during expression of amphetamine sensitization are the result of drug hypersensitivity. Eur J Neurosci. 2002;16:2462-2468. (Pubitemid 36056970)
34. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997;16:93-110; discussion 111-135. (Pubitemid 27088199)
35. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther. 2001;299:83-89. (Pubitemid 32905121)
36. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006;71:521-529. (Pubitemid 43077085)
37. Egerton A, Ahmad R, Hirani E, Grasby PM. Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl). 2008;200:487-496.
38. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl). 1996;124:87-94. (Pubitemid 26111437)
39. O'Brien CP, Childress AR, McLellan AT, Ehrman R. Classical conditioning in drug-dependent humans. Ann N Y Acad Sci. 1992;654:400-415.
40. Levison PK. An analysis of commonalities in substance abuse and habitual behavior. NIDA Res Monogr. 1981;37:27-41. (Pubitemid 12176376)
41. Tiffany ST, Carter BL. Is craving the source of compulsive drug use? J Psychopharmacol. 1998;12:23-30. (Pubitemid 28142996)
42. Duka T, Townshend JM. The priming effect of alcohol pre-load on attentional bias to alcohol-related stimuli. Psychopharmacology. 2004;176:353-361.
43. Field M, Cox WM. Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend. 2008;97:1-20.
44. Uslaner JM, Acerbo MJ, Jones SA, Robinson TE. The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine. Behav Brain Res. 2006;169:320-324.
45. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology. 2003;168:3-20. (Pubitemid 36851158)
46. Arroyo M, Markou A, Robbins TW, Everitt BJ. Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous access to cocaine. Psychopharmacology (Berl). 1998;140:331-344. (Pubitemid 28562453)
47. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry. 2002;159:1534-1540. (Pubitemid 35006734)
48. Smelson DA, Ziedonis D, Williams J, Losonczy MF, Steinberg ML, Kaune M. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26:9-12. (Pubitemid 43167083)
49. Noordsy DL, O'Keefe C, Mueser KT, Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv. 2001;52:501-507. (Pubitemid 32275312)
50. Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2011.
51. Rupniak NM, Hall MD, Mann S et al. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol. 1985;34:2755-2763. (Pubitemid 15041762)
52. Danna CL, Elmer GI. Disruption of conditioned reward association by typical and atypical antipsychotics. Pharmacol Biochem Behav. 2010;96:40-47.
53. Farde L, Wiesel FA, Nordstrom AL, Sedvall G. D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology. 1989;99, Suppl S28-S31. (Pubitemid 19244135)
54. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27-38. (Pubitemid 34302921)
55. Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. Toronto: Hogrefe & Huber Publishers; 1999.
56. Kirsch P, Ronshausen S, Mier D, Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry. 2007;40:196-198. (Pubitemid 47535746)
57. Schlagenhauf F, Juckel G, Koslowski M et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology. 2008;196:673-684.
58. Kelley AE, Delfs JM. Dopamine and conditioned reinforcement. I. Differential effects of amphetamine microinjections into striatal subregions. Psychopharmacology. 1991;103:187-196.
59. Parkinson JA, Olmstead MC, Burns LH, Robbins TW, Everitt BJ. Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by D-amphetamine. J Neurosci. 1999;19:2401-2411. (Pubitemid 29133415)